ClinicalTrials.gg
Active, not recruitingNCT05345509Updated Dec 19, 2024

A Clinical Trial to Access Pharmacokinetic Profiles and Safety of IVL3003.

A Phase 1/2 interventional study of Aricept Tablet and IVL3003 in Alzheimer Disease, sponsored by Inventage Lab., Inc.. Active, not recruiting at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Inventage Lab., Inc. · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
62
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 177 studies in Alzheimer Disease with a site in Australia — 23 open to participants now, 42 under way, 18 of them phase 3. Alzheimer Disease · Australia.

Planned enrollment
134th of 168
62 · median 313
Started
2023
with 7 others
Phase 1/2
4 of 177
none open now
Primary completion
2025-11
later than 2 of 41 live
Registered
129th of 177
by date

Among the 177 studies in Alzheimer Disease with a site in Australia, this one is the 134th largest by planned enrollment of the 168 interventional ones that give a count, is one of 8 that started in 2023, is one of 4 in phase 1/2, reaches primary completion later than 2 of the 41 other live ones, and was the 129th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

23 of the 177 studies in Alzheimer Disease with a site in Australia are open now. Recruiting first, the newest first:

18 more — sign in →

All 23 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 177 studies in Alzheimer Disease with a site in Australia, or all of them as a file.
02

Study summary

A Clinical Trial to Assess Pharmacokinetic Profiles and Safety of IVL3003

Read the detailed description

A Phase 1, Randomized, Open-Label, Exploratory, Sequential, Pharmacokinetic Single Ascending Dose Study of IVL3003 Versus Multiple Doses of Aricept (Donepezil) Tablets in Healthy Subjects

03

Conditions studied

  • Alzheimer Disease

Browse trials for

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy male or female, ≥18 and ≤55 years of age, non-smokers or occasional smokers (defined as smoking less than 10 cigarettes or nicotine equivalent per week, and willing to abstain from smoking during confinement at the study site).
  • (BMI) ≥18.0 and ≤32.0 kg/m2 and body weight ≥55.0 kg for males and ≥50.0 kg for females.
  • Male subjects who are sexually active with a same-sex partner must be willing to use a condom until study exit.
  • Male and female subjects who practice abstinence from sexual intercourse as a usual and preferred lifestyle.
  • Willing to abstain from use of non-steroidal anti-inflammatory drugs (NSAIDs) including ibuprofen, naproxen, aspirin, meloxicam, etc. from screening until study exit.
  • Willing and able to provide written after the nature of the study has been explained and prior to the commencement of any protocol specific study procedures.

Exclusion criteria

Exclusion Criteria:

  • Any abnormal finding at physical examination at screening.
  • Clinically significant abnormal laboratory test results or positive serology test results for (HIV), or virus at screening.
  • Positive pregnancy test at screening or Day -1 or lactating female subject.
  • Positive drug or alcohol screen at screening or Day -1.
  • Any history of or neoplastic disease.
  • History of significant allergic reactions (e.g., drug reaction, anaphylactic reaction, , angioedema) to donepezil, piperidine derivatives, dimenhydrinate or derivatives, benzatropine or derivatives, or other related drugs, or to any present in the formulation for any study drug.
  • Presence of hereditary disorders including galactose intolerance, lactase deficiency, and glucose-galactose malabsorption (for Part B only).
  • (ALT), aspartate aminotransferase (AST), or total >1.5x the (ULN) at screening or Day -1.
  • Estimated (eGFR) \<60 mL/min/1.73m2 as calculated by the 2021 Chronic Kidney Disease-Epidemiology (CKD-EPI) equation at screening or Day -1.
  • Clinically significant abnormalities ( >450 ms or PR interval >220 ms) or vital sign abnormalities (systolic blood pressure \<90 or >140 mmHg, diastolic blood pressure \<40 or >90 mmHg, or heart rate \<50 or >100 bpm) at screening or Day 1.
  • History of significant bradycardia or atrioventricular (AV) block.
  • History of significant asthma (except for fully resolved childhood asthma) or (COPD).
  • History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 14 units of alcohol per week (1 unit = 375 mL of beer 3.5%, 100 mL of wine 13.5%, or 30 mL of spirit 40%).
  • History of drug abuse within 1 year prior to screening or recreational use of soft drugs (such as marijuana) or hard drugs (such as cocaine, phencyclidine [PCP], crack, opioid derivatives including heroin, and amphetamine derivatives) within 1 month, or use of codeine within 3 months prior to screening.
  • Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 30 days prior to dosing.
  • Consumption of high levels of caffeine (equivalent to 3 regular cups of coffee or 2 energy drinks, per day).
  • Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
62 participants (estimated)

Study arms

  • Active comparator
    Aricept Tablet

    Aricept Tablet, QD, PO

    Drug: Aricept Tablet

  • Experimental
    IVL3003 (A mg)

    SC, Single Dose

    Drug: IVL3003

  • Experimental
    IVL3003 (B mg)

    SC, Single Dose

    Drug: IVL3003

  • Experimental
    IVL3003 (C mg)

    SC, Single Dose

    Drug: IVL3003

  • Experimental
    IVL3003 (Dmg)

    Intramuscular

    Drug: IVL3003

  • Experimental
    IVL3003 (Emg)

    Intramuscular

    Drug: IVL3003

Interventions

  • DrugDonepezilStudies of DonepezilDonepezil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Donepezil Tablet once daily P.O

  • DrugIVL3003

    Donepezil Long-Acting Injection, once S.C Injection

  • DrugIVL3003

    Donepezil Long-Acting Injection, once IM Injection

06

What researchers measure

Primary outcomes

  1. AUClast of IVL3003

    Area under the concentration-time curve from time zero to last

    Time frame: Pre-dose, up to 1month

  2. AUCinf of IVL3003

    Area under the concentration-time curve from time zero to infinity

    Time frame: Pre-dose, up to 1month

  3. AUClast of Aricept

    Area under the concentration-time curve from time zero to last

    Time frame: Pre-dose, up to 1month

  4. AUCinf of Aricept

    Area under the concentration-time curve from time zero to infinity

    Time frame: Pre-dose, up to 1month

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2023 (actual). Primary completion is estimated for Nov 2025, 31 months after the start.

Of 62 phase 1/2 interventional studies under Alzheimer Disease, half reached primary completion within 45 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 63. This study's planned 31 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 19, 2022
First posted
Apr 26, 2022
StartActual
Apr 1, 2023
Primary completionEst.
Nov 13, 2025
CompletionEst.
Nov 13, 2025
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05345509
Lead sponsor
Inventage Lab., Inc.
Responsible party
Sponsor
First posted
Apr 26, 2022
Start date
Apr 1, 2023
Primary completion
Nov 13, 2025 (estimated)
Completion
Nov 13, 2025 (estimated)
Last update
Dec 19, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Dec 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion